An observational study in Hereditary Haemorrhagic Telangiectasia (HHT), sponsored by Ashley Nelson. Recruiting at 1 site in United States. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ashley Nelson · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States — 5 open to participants now, 8 under way, 1 of them phase 3. Telangiectasia, Hereditary Hemorrhagic · United States.
Among the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, this one is one of 3 that started in 2026, is one of 9 observational ones, and was the 26th registered.
106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.
Browse Telangiectasia, Hereditary Hemorrhagic studies →5 of the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States are open now. Recruiting first, the newest first:
Vaderis Therapeutics AG · Sites in United States, Belgium, France and 6 more countries
Ages 18+
Atavistik Bio, Inc · Sites in United States, Argentina
Ages 18+ · Healthy volunteers
Cure HHT · Sites in United States
Healthy volunteers
Columbia University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 2 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 207 across 41 observational studies indexed under Telangiectasia, Hereditary Hemorrhagic.
Median enrollment 27 across the 20 interventional studies, 223 across the 9 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ashley Nelson as lead sponsor.
Ashley Nelson has 1 study filed under Telangiectasia, Hereditary Hemorrhagic — fewer than ten, so there is no comparison to draw.
2 of the studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07474428Ashley NelsonQuality of Life in Pediatric Participants With HHT | 2026-12 |
| NCT05406362Vaderis Therapeutics AGAssess Safety and Efficacy of VAD044 in HHT Patients | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT). Eligible participants are patients receiving care at Cincinnati Children's Hospital Medical Center and / or their caregivers. Participants will complete validated quality-of-life questionnaires assessing physical, emotional, social, and disease-specific functioning over the past 30 days. A paired retrospective chart review will assess disease severity and clinical utilization, including procedures and imaging studies. The primary objective is to describe mean QoL scores for this population. Secondary objectives include evaluating associations between QoL scores, disease severity, and clinical utilization.
The study population will include pediatric and young adult patients aged 2-25 years with a confirmed diagnosis of Hereditary Hemorrhagic Telangiectasia receiving care at Cincinnati Children's Hospital Medical Center. Eligible participants will be identified through the electronic medical record based on diagnostic criteria and clinic records. Both caregiver proxy respondents (for children aged 2-17 years) and patient self-report respondents (for individuals aged 8-25 years) will be included. Participants will complete validated quality-of-life questionnaires assessing health-related and disease-specific quality of life over the prior 30 days. A paired retrospective chart review will be conducted to obtain clinical variables including disease severity, procedures, imaging studies, and other healthcare utilization measures associated with HHT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient aged 2-25 years with a confirmed (either genetic or clinical) diagnosis of definite HHT
Exclusion Criteria:
PedsQL Total Score
Mean total health-related quality of life score measured using the Pediatric Quality of Life Inventory (PedsQL). Scores range from 0-100, with lower scores indicating worse quality of life.
Time frame: 30 days
HHT-QOL
Mean score ranging from 0-16 assessing HHT-related symptom burden and functional impact. Higher scores indicate worse impairment.
Time frame: past 30 days
Epistaxis Severity Score
Continuous score (0-10) measuring nosebleed severity. Higher scores indicate more severe epistaxis.
Time frame: past 30 days
HHT Severity Score
Continuous score ranging 0-7 reflecting lifetime disease severity based on organ AVMs and bleeding history.
Time frame: lifetime
Clinical Utilization
Number of procedures (embolization, cauterization) and imaging studies (MRI, CT, bubble echocardiography).
Time frame: lifetime
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Telangiectasia, Hereditary Hemorrhagic →